AFMD News and Press, Affimed N.V. From 11/03/22

Germany's Affimed ( NASDAQ: AFMD ) stock rose ~22% on Thursday after the company said it signed an agreement with San Diego-based Artiva Biotherapeutics to jointly develop and commercialize a combination therapy to treat cancer. The combo therapy consists of Aff...

Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patients Affimed’s AFM13 in combination with cord blood-derived NK cells demonstrated exceptionally high response rates in relapsed and refractory CD30-positive l...

In 24 patients with CD30-positive lymphoma treated at the highest dose level, the combination treatment of AFM13 with allogeneic NK cells continues to achieve a 100% overall response rate and an improved 70.8% complete response rate Patients received up to four cycles and the trea...

HEIDELBERG, Germany, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Execu...

Summary Two poster presentations showing AFM24 as a monotherapy and combination treatment will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, November 8-12, 2022. Results from the phase 2 registration REDIRECT study using AFM13 as a monotherapy...

Affimed Therapeutics stock ( NASDAQ:AFMD ) appeared ailing in the stock market on Monday. The company’s U.S.-traded shares fell more than 16% as a result of a pretty depressing fresh analyst assessment. So, what’s the deal with Affimed Stock? ...

European biotech Affimed Therapeutics (NASDAQ: AFMD) was looking a bit sickly on our stock exchange Monday. The company's U.S.-traded shares suffered a more than 16% decline, on the back of a rather dispiriting new take from an analyst. The prognosticator in question is Stifel...

Stifel has downgraded Affimed N.V. ( NASDAQ: AFMD ) to hold from buy as the firm no longer believes that three upcoming data updates will be positive for the biotech. Stifel also cut its price target for the biotech to $2 from $9 (5% upside based on Friday's close). An...

A poster evaluating comprehensive correlative science findings from the AFM24 monotherapy phase 1 study (AFM24-101) will be presented In a second poster presentation, initial phase 1 dose escalation study results of AFM24 in combination with Roche’s checkpoint inhibitor atezoli...

Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reached Stable disease was observed in 10 of 27 evaluable patients in an unselected patient population Comprehensive pharmacodynamic studies ind...